{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:13:17Z","timestamp":1789002797106,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jval.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T01:50:58Z","timestamp":1532569858000},"page":"1373-1381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric\/Pharmacoeconomic Model"],"prefix":"10.1016","volume":"21","author":[{"given":"Daniel","family":"Hill-McManus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyfrig","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2018.06.002_bib1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jval.2018.06.002_bib2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/rheumatology\/kex150","article-title":"The British Society for Rheumatology Guideline for the Management of Gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.jval.2018.06.002_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2018.06.002_bib4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2018.06.002_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006077.pub3","article-title":"Allopurinol for chronic gout","author":"Seth","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jval.2018.06.002_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.semarthrit.2014.05.007","article-title":"Impaired response or insufficient dosage? Examining the potential causes of \u201cinadequate response\u201d to allopurinol in the treatment of gout","volume":"44","author":"Stamp","year":"2014","journal-title":"Semin Arthitis Rheum"},{"key":"10.1016\/j.jval.2018.06.002_bib7","doi-asserted-by":"crossref","first-page":"e017542","DOI":"10.1136\/bmjopen-2017-017542","article-title":"Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis","volume":"8","author":"Yin","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2018.06.002_bib8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","article-title":"Medication adherence among patients with gout: a systematic review and meta-analysis","volume":"47","author":"Scheepers","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jval.2018.06.002_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jval.2018.06.002_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bcp.12942","article-title":"A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence","volume":"82","author":"El Alili","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jval.2018.06.002_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrd.2017.1","article-title":"Poor medication adherence in clinical trials: consequences and solutions","volume":"16","author":"Breckenridge","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jval.2018.06.002_bib12","series-title":"Febuxostat for the Management of Hyperuricaemia in People with Gout: Technology Appraisal Guidance","year":"2008"},{"key":"10.1016\/j.jval.2018.06.002_bib13","series-title":"Lesinurad for Treating Chronic Hyperuricaemia in People with Gout: First Appraisal Consultation Document","year":"2016"},{"key":"10.1016\/j.jval.2018.06.002_bib14","series-title":"Final Appraisal Determination: Lesinurad for Treating Chronic Hyperuricaemia in People with Gout","year":"2017"},{"key":"10.1016\/j.jval.2018.06.002_bib15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1524-4733.2007.00205.x","article-title":"Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations","volume":"10","author":"Hughes","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.06.002_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bcp.13427","article-title":"Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout","volume":"84","author":"Hill-McManus","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jval.2018.06.002_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10198-014-0617-1","article-title":"Cost-effectiveness of febuxostat in chronic gout","volume":"15","author":"Beard","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2018.06.002_bib18","unstructured":"National Institute for Health and Care Excellence. Single Technology Appraisal [ID761]: Lesinurad for treating chronic hyperuricaemia in people with gout, Committee Papers.\u00a02016."},{"key":"10.1016\/j.jval.2018.06.002_bib19","series-title":"NONMEM 7.3.0 Users Guides (1989\u20132013)","author":"Beal","year":"2013"},{"key":"10.1016\/j.jval.2018.06.002_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bcp.12799","article-title":"Predicting allopurinol response in patients with gout","volume":"81","author":"Wright","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jval.2018.06.002_bib21","series-title":"Pharmacokinetic and Pharmacodynamic Data Analysis","author":"Gabrielsson","year":"2016"},{"key":"10.1016\/j.jval.2018.06.002_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jval.2018.06.002_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.jval.2018.06.002_bib24","first-page":"1799","article-title":"Diagnosis and management of gout","volume":"59","author":"Pittman","year":"1999","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jval.2018.06.002_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2018.06.002_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jval.2018.06.002_bib27","series-title":"Guide to the Methods of Technology Appraisal 2013","year":"2013"},{"key":"10.1016\/j.jval.2018.06.002_bib28","series-title":"R: A Language and Environment for Statistical Computing","year":"2017"},{"key":"10.1016\/j.jval.2018.06.002_bib29","year":"2015","journal-title":"Zurampic label (Reference ID: 3864748)"},{"key":"10.1016\/j.jval.2018.06.002_bib30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jval.2018.06.002_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","article-title":"The effect of serum urate on gout flares and their associated costs: an administrative claims analysis","volume":"15","author":"Halpern","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jval.2018.06.002_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7525-10-117","article-title":"Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey","volume":"10","author":"Khanna","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2018.06.002_bib34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3899\/jrheum.160452","article-title":"Serum uric acid and the risk of incident and recurrent gout: a systematic review","volume":"44","author":"Shiozawa","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jval.2018.06.002_bib35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.jval.2018.06.002_bib36","unstructured":"Joint Formulary Committee. British National Formulary. Available from: http:\/\/www.medicinescomplete.com. [Accessed August 3, 2017]."},{"key":"10.1016\/j.jval.2018.06.002_bib37","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout, part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jval.2018.06.002_bib38","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2018.06.002_bib39","doi-asserted-by":"crossref","first-page":"j2376","DOI":"10.1136\/bmj.j2376","article-title":"Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies","volume":"357","author":"Li","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2018.06.002_bib40","series-title":"Guide to the Single Technology Appraisal Process","year":"2009"},{"key":"10.1016\/j.jval.2018.06.002_bib41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/11591540-000000000-00000","article-title":"Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic\/pharmacodynamic\/pharmacoeconomic analysis of rituximab for follicular lymphoma","volume":"30","author":"Pink","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2018.06.002_bib42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/clpt.2013.190","article-title":"Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation","volume":"95","author":"Pink","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jval.2018.06.002_bib43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/psp4.48","article-title":"Integrated simulation framework for toxicity, dose intensity, disease progression, and cost effectiveness for castration-resistant prostate cancer treatment with eribulin","volume":"4","author":"van Hasselt","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jval.2018.06.002_bib44","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jval.2016.07.006","article-title":"Translating pharmacometrics to a pharmacoeconomic model of COPD","volume":"19","author":"Slejko","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.06.002_bib45","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bcp.13229","article-title":"Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics","volume":"83","author":"Kamal","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jval.2018.06.002_bib46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jval.2014.03.1721","article-title":"Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios","volume":"17","author":"Hoogendoorn","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.06.002_bib47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/clpt.2010.114","article-title":"Clinical trial simulation: a review","volume":"88","author":"Holford","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jval.2018.06.002_bib48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1742-7843.2005.pto960312.x","article-title":"The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic\/pharmacodynamic analyses","volume":"96","author":"Vrijens","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jval.2018.06.002_bib49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/psp4.4","article-title":"Quantification of the forgiveness of drugs to imperfect adherence","volume":"4","author":"Assawasuwannakit","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jval.2018.06.002_bib50","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40273-017-0526-0","article-title":"Prioritizing future research on allopurinol and febuxostat for the management of gout: value of information analysis","volume":"35","author":"Jutkowitz","year":"2017","journal-title":"Pharmacoeconomics"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830151832240X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830151832240X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T15:13:53Z","timestamp":1575299633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830151832240X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S109830151832240X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2018.06.002","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric\/Pharmacoeconomic Model","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}